Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
About
Articles
Low Density Lipoprotein Cholesterol and Coronary Heart Disease - Lower is Better
Citation:
European Cardiology 2005:1(1):1-6
- Abstract
- Full text
- Login or register to view PDF.
- Permissions
- References
Permissions×
For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.
For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.
For author reprints, please email rob.barclay@radcliffe-group.com.
For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.
For author reprints, please email rob.barclay@radcliffe-group.com.
- Views: 12610
- Downloads: 0
- Citations: 1
-
Read time: 1h 1m 1s